Eisai Co., Ltd. revised consolidated financial forecasts for the fiscal year ended March 31, 2022. For the period, the company revised Revenue to ¥756,000 million from ¥730,000 million, Operating profit to ¥53,500 million from ¥78,000 million, Profit for the period to ¥45,500 million from ¥61,000 million and Basic earnings per share to ¥167.30 from ¥211.00.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,764 JPY | -0.43% | +2.56% | -4.08% |
May. 06 | People with two copies of a risk gene have genetic form of Alzheimer's, scientists say | RE |
Apr. 24 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.08% | 12.5B | |
+30.38% | 684B | |
+29.82% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.34% | 240B | |
+8.94% | 208B | |
-7.61% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- Eisai Co., Ltd. Revises Consolidated Financial Forecasts for the Fiscal Year Ended March 31, 2022